IPSEN S A/S (OTCMKTS:IPSEY) Rating Lowered to Equal Weight at Barclays

IPSEN S A/S (OTCMKTS:IPSEY) was downgraded by equities researchers at Barclays from an “overweight” rating to an “equal weight” rating in a research note issued on Monday, The Fly reports.

Separately, ValuEngine raised IPSEN S A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Five investment analysts have rated the stock with a hold rating, IPSEN S A/S has a consensus rating of “Hold”.

Shares of IPSEY stock opened at $22.09 on Monday. IPSEN S A/S has a 1 year low of $21.59 and a 1 year high of $35.97. The stock has a market cap of $7.80 billion, a PE ratio of 12.70 and a beta of 0.56. The business’s fifty day moving average is $26.46 and its 200-day moving average is $27.89.

IPSEN S A/S Company Profile

Ipsen SA operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity.

Featured Story: Key terms to understand channel trading

The Fly

Receive News & Ratings for IPSEN S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN S A/S and related companies with MarketBeat.com's FREE daily email newsletter.